Skip to main content

Advertisement

Table 5 Risk factors tested for association with 5-FU- and capecitabine-associated cardiotoxicity

From: Cardiotoxicity of 5-fluorouracil and capecitabine in Chinese patients: a prospective study

Variable Patients with cardiotoxicity (n = 161) Patients without cardiotoxicity (n = 366) P
Chemotherapy
 5-Fluorouracil 49 (30.4) 147 (40.2) 0.033
 Capecitabine 112 (69.6) 219 (59.8)  
Chemotherapy cycle
 1–4 53 (32.9) 143 (39.1) 0.386
 5–9 91 (56.5) 177 (48.4)  
 ≥ 9 9 (5.6) 26 (7.1)  
 UK 8 (5.0) 20 (5.5)  
Concurrent radiotherapy
 Yes 6 (3.7) 16 (4.4) 0.733
 No 155 (96.3) 350 (95.6)  
Sex
 Male 108 (67.1) 240 65.6) 0.737
 Female 53 (32.9) 126 (34.4)  
Age, years
 ≤ 29 4 (2.5) 6 (1.6) 0.257
 30~ 9 (5.6) 23 (6.3)  
 40~ 33 (20.5) 79 (21.6)  
 50~ 40 (24.8) 110 (30.1)  
 60~ 54 (33.5) 124 (33.9)  
 70~ 19 (11.8) 23 (6.3)  
 80~ 2 (1.2) 1 (0.3)  
Pre-existing disease
 Hypertension
  Yes 44 (27.3) 62 (16.9) 0.006
  No 117 (72.7) 304 83.1)  
 Diabetes
  Yes 11 (6.8) 18 (4.9) 0.375
  No 150 (93.2) 348 (95.1)  
 Cardiac disease
  Yes 9 (5.6) 4 (1.1) 0.004
  No 152 (94.4) 362 (98.9)  
 Hyperlipidemia
  Yes 2 (1.2) 2 (0.5) 0.762
  No 159 (98.8) 364 (99.5)  
Surgical history
 Yes 129 (80.1) 286 (78.1) 0.608
 No 32 (19.9) 80 (21.9)  
Treatment history
 Chemotherapy
  Yes 33 (20.5) 85 (23.2) 0.521
  No 128 (79.5) 281 (76.8)  
 Radiotherapy
  Yes 9 (5.6) 23 (6.3) 0.759
  No 152 (94.4) 343 (93.7)  
 Chemotherapy and radiotherapy
  Yes 7 (4.3) 19 (5.2) 0.808
  No 154 (95.7) 347 (94.8)